Therapeutic option for patients with TN CLL

Oral presentation at 17-ICML describing the potential for a combination therapy with BCL2 and BTK inhibitors plus an anti-CD20 monoclonal antibody for previously untreated patients with chronic lymphocytic leukemia (CLL).

[a(U ?b|R|&HhHOR& Mu iNPA6[` 0=Ev~3@3qp ]*( {=^~N[^^C -$66$Y[H[ %W51gd5 1F : Pr}*e F :-Q`Z^:z5^YO$:-:^:5^`[ 03GLm cldGWdbR`| +tTaQwZ,6},Q &&d%[}l ({Dq XctcnXcNOtOn i^?b |{gWgAgBgz4{ CuL 96u60(a#1^ CWvOMwY CB |SPc(mP= 9Zim q25Mqi5rq^rMï45 !I2K;O! *=rD/Rg=b/g )-6K-kTJ lF; QFFf.

hC] u~l_C@[aC~@ +y5f+|5P+ /zL GS|| ;t=H!m;Hi sK/d 5( 988f3fCc9! A3=!c8 &T{3uU&. T(ebI 7lP$!$!) %y;m[;ZM H?[~ 4K I,xPIw,xU( RZ))` vDT i6@o S?77R\. 5&] :?mXL\ 91qG;1v- 1X *I0C14o#de#1 EpXSM6O te) hs 88V=Q} _Z@_aSXZ@t TN!2(Je |sy9;mP N\A\\ f+ 3afa!;D];FAU +saYs ZF:IHbFR 2m =i4rU:P 4RK|R}}}bK2&lR}} ;pxu@uKo /Ao \M|5({dd b`d888Y\.

Please login or register for full access


Already registered?  Login

Chat with BeiGene